Reckitt CFO Day departs
This article was originally published in The Tan Sheet
Executive Summary
Colin Day, Reckitt Benckiser's chief financial officer for 10 years, will leave the organization, the U.K. company says Oct. 22. Day, who as CFO has seen the firm significantly expand its pharmaceutical business, will remain in the position until March 2011 to ensure a smooth transition. A successor will be announced in the next few months, the firm said
You may also be interested in...
Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
Emerging markets, the key driver for Reckitt Benckiser's nearly 20% net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.